Say Goodbye to Bydureon and Byetta

Discussion in 'AstraZeneca' started by anonymous, Feb 16, 2016 at 7:01 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    maybe we could sell Tanzeum...a dog like ours.

    Plus Novo hitting the skids...a real CF!
     

  2. anonymous

    anonymous Guest

    ITCA650 will have less efficacy than Bydureon. The company will be looking to have device sales people or clinicians to sell it. AZ tried to sell Bydureon to Novartis in Q4 and they didn't want it. I have no conspiracy theories, just facts. It's all about Farxiga in the Diabetes portfolio.
     
  3. anonymous

    anonymous Guest

    The arrogant buffoon marketing boys are not hiring reps but reported 200-250 nurses to train (more like assist) the targeted endocrinologists most of whom are leery of performing the minor surgery in their office.

    Those aholes at Intarcia believe in heavy dose of BS marketing campaigns and no doubt pressure the payors to cover it by pseudo propaganda of the lemming patients (all paid of course).

    As for the GLP-1 drugs - it's a damn commodity with race to the bottom...
     
  4. anonymous

    anonymous Guest

    With the new news that Trulicity can now be used in patients that are on a basil insulin, Bydureon is done!! D O N E. Jardiance kicking Farxiga's ass. Diabetes is toast. Good luck in the job market folks. AZ Diabetes is a second rate Pharma division.
     
  5. anonymous

    anonymous Guest

    Got news for you. Every division is second rate. Is PCP considered the "respiratory" company? We all know GSK owns us. And w/ Advair generic coming, it will be ugly fast. Bevespi- Tosh and the brand team said we have 12 weeks to show what we can do. Way to motivate a sales force. So what will happen at the end of March Tosh. We know numbers won't hit the inflated forecast.
    Oncology? The new PARP inhibitor will make Lynparza look silly. Durvalumab is not living up to the hype. Only Tagrisso is worth anything of substance.

    Hope that the severance package stays the same because December was just the warm-up.
     
  6. anonymous

    anonymous Guest

    July was the warm up and December was the first run at the layoff machine. That being said, you are correct, the ball is just starting to roll!!
     
  7. anonymous

    anonymous Guest

    Jeez bending over backwards to be negative when you know Intarcia will DISRUPT and OWN the market delivering on the PROMISE of clinical trial data in the real world with IMPLANTS that DELIVER !!

    Look if you want a state-o-f-the- art sales job that will REVOLUTIONIZE diabetes - come to Intarcia - THE FUTURE OF HEALTHCARE
     
  8. anonymous

    anonymous Guest

    John Y says the group is fired up
     
  9. anonymous

    anonymous Guest

    Quite interesting, and obviously makes sense, to see Intarcia's Field Medical personnel staffed by former Amylin MSLs. Once they begin building their sales force, I bet they'll be reaching out to Amylin Legacy reps.
     
  10. anonymous

    anonymous Guest

    Not just former Amylin.. former AstraSatanica colleagues.. welcome to HELL
     
  11. anonymous

    anonymous Guest

    You need an exorcist! You are possessed by evil, for sure. Your anger is devilish.
     
  12. anonymous

    anonymous Guest

    Is John Y a good source for climate/prospects ? Have interview with him and want to get a better read before joining.
     
  13. anonymous

    anonymous Guest

    who is recruiter for this job ?
     
  14. anonymous

    anonymous Guest

     
  15. anonymous

    anonymous Guest

    Mirena is an IUD... intra - uterine - device. Not anywhere near the same. Dummy.
     
  16. anonymous

    anonymous Guest

    With the recent failure of Bydureon to reach a CV benefit in MACE, good luck selling this D O G of a drug.
     
  17. anonymous

    anonymous Guest

    With the recent failure of Bydureon to reach a CV benefit in MACE, good luck selling this D O G of a drug.[/QUOTE]

    Ruff Ruff !! The Future is Named... I..N...T..A...R...C...I...A Lokking to be #1 in Diabetes with a solution for compliance

    Disruptive, Break through, better than GOOGLE brighter future than AMAZON

    Get in on the ground floor

    INTARCIA

    INTARCIA